With Treatment
Denovo is treatment facility located at 339 East 3900 South, Suite 155 in the 84107 zip code in Salt Lake City, UT that offers medication-assisted addiction treatment. It accepts people with co-occurring substance use and mental disorders into its treatment service. Denovo provides buprenorphine detox, naltrexone administration and methadone maintenance to young adults and adults. Some of the treatment approaches used by Denovo consist of motivational interviewing, substance use counseling and relapse prevention. Denovo also provides detoxification services and offers opioid detox.
Address: 339 East 3900 South, Suite 155, Salt Lake City, UT 84107
Here are the full facility listing details on DeNovo in Salt Lake City, UT:
Types of Care at Denovo
Service Settings at Denovo
Opioid Medications used in Treatment at Denovo
Type of Alcohol Use Disorder Treatment at Denovo
Type Of Treatment at Denovo
Pharmacotherapies at Denovo
Treatment Approaches at Denovo
FacilityOwnership at Denovo
License/Certification/Accreditation at Denovo
Payment/Insurance/Funding Accepted at Denovo
Special Programs/ Population Groups Supported at Denovo
Assessment/Pre-treatment at Denovo
Screening & Testing at Denovo
Transitional Services at Denovo
Ancillary Services at Denovo
Other Addictions Treatment at Denovo
Detoxification at Denovo
Counseling Services and Education at Denovo
Tobacco/Screening Services at Denovo
Facility Smoking Policy at Denovo
Age Groups Accepted at Denovo
Gender Accepted at Denovo
Exclusive Services at Denovo
Services for deaf at Denovo
Phone #: 801-263-1056
Call (866) 434-2077 for 24/7 help with treatment.
Methadone treatment can be a safe and effective option for individuals struggling with opioid addiction, especially when administered under the supervision of a qualified healthcare provider as part of a comprehensive addiction treatment program, such as the one that can be found at DeNovo. Methadone is an opioid medication that is used to help manage opioid withdrawal symptoms and cravings, making it easier for individuals to reduce or quit their use of other opioids like heroin or prescription painkillers.
Here are some key points to consider regarding the safety of methadone treatment:
Supervised Administration: Methadone treatment is typically provided through opioid treatment programs (OTPs) or clinics where patients receive a daily dose of methadone under the supervision of healthcare professionals. This helps reduce the risk of misuse and overdose.
Reduces Withdrawal Symptoms: Methadone can alleviate the severe withdrawal symptoms associated with opioids, which can be a significant barrier to recovery. This can enhance the patient's quality of life and make it easier for them to engage in therapy and counseling.
Harm Reduction: Methadone maintenance treatment can be viewed as a harm reduction approach. While it doesn't necessarily lead to immediate abstinence, it reduces the risks associated with illicit opioid use, such as overdose and the transmission of infectious diseases (e.g., HIV and hepatitis).
Individualized Treatment: Methadone treatment should be individualized to meet the unique needs of each patient. The dose is typically adjusted based on the patient's response and progress in treatment.
Legal Regulation: Methadone clinics and providers are subject to strict regulations and oversight by government agencies to ensure safety and appropriate use of the medication.
However, it's important to note that methadone is an opioid itself and can be habit-forming. When taken as prescribed and under medical supervision, the risk of addiction to methadone is relatively low. However, misuse or diversion of methadone can lead to addiction and other negative consequences.
Methadone treatment is not suitable for everyone. Individuals with certain medical conditions or contraindications may not be candidates for methadone treatment. It's essential for addiction treatment centers like DeNovo to conduct a thorough assessment before starting someone on methadone.
Other drug and rehab centers within 75 miles of DeNovo: